Natera, Inc.
NTRA
Positions held
Your positionsNTRA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Natera, Inc. is positioned in the rapidly growing diagnostics and research sector, which is expected to expand significantly as personalized medicine and genetic testing gain traction.
- Natera's revenue grew by 8% in the last quarter, reaching $753 million, indicating strong demand for its services.
- The company's gross margin remains robust at 64.5%, showcasing its ability to maintain profitability despite challenges.
- Despite its growth potential, Natera has a high debt-to-equity ratio of 13.093, which may raise concerns about financial stability.
- The company reported a net income loss of $66.969 million in the most recent quarter, reflecting ongoing profitability challenges.
- Natera's operating margin was -10.1% last quarter, indicating that it is still struggling to achieve operational efficiency.
Fundamentals
| Market cap | $56.33B | Enterprise value | $55.48B | Trailing P/E | — | Forward P/E | -1,978.68 |
| PEG | — | Price / book | 30.81 | Beta | 1.50 | Dividend yield | 0.00% |
| Revenue growth | 37.7% | Earnings growth | — | Gross margin | 65.2% | Operating margin | -10.3% |
| Profit margin | -7.1% | ROE | -12.5% | ROA | -8.1% | Debt / equity | 0.13 |
| Current ratio | 3.00 | Free cash flow | $104.03M | Analyst recommendation | strong_buy | Mean target | $383.66 |
| 52w high | $437.41 | 52w low | $167.99 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $753M | $697M | $665M | $592M | $547M | — |
| Op margin | -10.1% | -13.4% | -3.4% | -16.5% | -20.2% | — |
| Net income | -$67.0M | -$85.1M | $47.3M | -$87.5M | -$101M | — |
| Gross margin | 64.5% | 64.7% | 66.9% | 64.9% | 63.4% | — |
| Gross profit | $485M | $451M | $445M | $384M | $347M | — |
| Operating income | -$75.8M | -$93.5M | -$22.8M | -$97.6M | -$110M | — |
- Revenue +8% vs prior quarter ($753M vs $697M).
- Gross margin 64.5% (was 64.7% prior quarter).
- Operating margin expanded to -10.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.3B | $1.7B | $1.1B | $820M | — |
| Op margin | -13.4% | -13.1% | -41.2% | -66.0% | — |
| Net income | -$208M | -$190M | -$435M | -$548M | — |
| Gross margin | 64.7% | 60.3% | 45.5% | 44.4% | — |
| Gross profit | $1.5B | $1.0B | $493M | $364M | — |
| Operating income | -$310M | -$222M | -$446M | -$541M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · 3 Market-Beating Stocks with Competitive Advantages
2026-10-07 · Natera Study of Signatera to Identify Skin Cancer Earlier Begins Enrollment
2026-10-07 · Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
2026-10-06 · 1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
2026-10-06 · New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
2026-10-05 · 2 Growth Stocks to Stash and 1 That Underwhelm
2026-10-05 · Natera Launches Phase III MRD-Guided Breast Cancer Trial Using Signatera
2026-10-05 · Natera, Alliance Foundation Trials Launch Phase 3 Trial for Breast Cancer Treatment Strategy
2026-10-02 · 3 Great Healthcare Stocks To Own In October 2026
2026-09-30 · 1 Unprofitable Stock to Target This Week and 2 We Question
Price (daily)
Full chart · RSI · MACD · patterns